abstract: This paper analyses the pathological features and prognosis in 3,147 cases of @entity3 collected from thirteen colleges, institutes and hospitals. The results reveal: The mean 5 year survival rate of 3,147 cases of @entity3 is 50.21%. The age of @entity0 , @entity2 location, size, gross typing, histologic classification, growth pattern, the depth of infiltration, the @entity1 into lymph nodes, the lymphocyte infiltration and fibrous proliferation surrounding the @entity2 are all prognostic. The depth of infiltration and @entity1 into lymph nodes are the chief determinant of prognosis. The prognosis is much better in cases without penetrating the musculature or prognosis. The prognosis is much better in cases without penetrating the musculature or @entity1 into lymph nodes than otherwise. It is better in those with metastases into 1-2 2 lymph nodes than with 3 or more. The histological types reflect the biologic nature of the @entity2 , exercising the most decisive influence upon the prognosis. The various pathologic changes are all closely associated with it. There is much difference in prognosis among well, moderately and poorly differentiated @entity4 (70.3%, 49.6% and 26.6%) whereas almost no difference exists among the different histologic types with the same degree of differentiation. This indicates that it is the @entity2 differentiation which plays the important role in the prognosis. 4. The immune response in the regional lymph nodes, the lymphocyte infiltration and fibrous proliferation surrounding the @entity2 reflect the immune status of the organism against the @entity2 and favorably affect the prognosis.

title: [Prognostic significance of pathology in 3, 147 cases of XXXX . National Cooperative Group on Pathology and Prognosis of @entity3 ].

answer: @entity3


abstract: This paper analyses the pathological features and prognosis in 3,147 cases of @entity3 collected from thirteen colleges, institutes and hospitals. The results reveal: The mean 5 year survival rate of 3,147 cases of @entity3 is 50.21%. The age of @entity0 , @entity2 location, size, gross typing, histologic classification, growth pattern, the depth of infiltration, the @entity1 into lymph nodes, the lymphocyte infiltration and fibrous proliferation surrounding the @entity2 are all prognostic. The depth of infiltration and @entity1 into lymph nodes are the chief determinant of prognosis. The prognosis is much better in cases without penetrating the musculature or prognosis. The prognosis is much better in cases without penetrating the musculature or @entity1 into lymph nodes than otherwise. It is better in those with metastases into 1-2 2 lymph nodes than with 3 or more. The histological types reflect the biologic nature of the @entity2 , exercising the most decisive influence upon the prognosis. The various pathologic changes are all closely associated with it. There is much difference in prognosis among well, moderately and poorly differentiated @entity4 (70.3%, 49.6% and 26.6%) whereas almost no difference exists among the different histologic types with the same degree of differentiation. This indicates that it is the @entity2 differentiation which plays the important role in the prognosis. 4. The immune response in the regional lymph nodes, the lymphocyte infiltration and fibrous proliferation surrounding the @entity2 reflect the immune status of the organism against the @entity2 and favorably affect the prognosis.

title: [Prognostic significance of pathology in 3, 147 cases of @entity3 . National Cooperative Group on Pathology and Prognosis of XXXX ].

answer: @entity3


abstract: The aim of this study was to verify the effect of nasally instilled liposomes (L) or @entity2 -containing L (Ldexa) on normal or inflamed lung tissue. Three groups of @entity0 were studied. Group I was given saline instillations for 3 weeks prior to the instillation with liposomes. In @entity1 was induced by repeated instillations of Saccharopolyspora rectivirgula before the instillation of liposomes (group II) or liposomes containing @entity2 (group III). Animals from all groups were killed at regular time intervals for up to 48 h after the instillation of liposomes. The total cell count in bronchoalveolar lavage fluid did not differ significantly between groups I and II. However, in group III it decreased rapidly from 6.2 to 2.8 x 10(5) cells @entity4 within 2 h. Differential counts did not change in group I, but in group II a transient neutrophilia was observed 180 min after the instillation of liposomes. In group III, the instillation of @entity2 -containing liposomes depleted all neutrophils and lymphocytes after 4 h. No @entity3 was found in samples of lavage fluid from any of the groups at time 0. In group I, liposomes induced the production of 0.03 ng @entity4 of @entity3 in the 1 h sample only. In group II, @entity3 peaked to 1 ng @entity4 at 1 h and had decreased to 0.35 ng @entity4 by 3 h. In group III, @entity3 peaked at 1 h, but only reached a level of 0.1 ng @entity4 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: PC:PS liposomes induce a recruitment of neutrophils and the release of XXXX in the lungs of @entity0 sensitized with Saccharopolyspora rectivirgula.

answer: @entity3


abstract: The aim of this study was to verify the effect of nasally instilled liposomes (L) or @entity2 -containing L (Ldexa) on normal or inflamed lung tissue. Three groups of @entity0 were studied. Group I was given saline instillations for 3 weeks prior to the instillation with liposomes. In @entity1 was induced by repeated instillations of Saccharopolyspora rectivirgula before the instillation of liposomes (group II) or liposomes containing @entity2 (group III). Animals from all groups were killed at regular time intervals for up to 48 h after the instillation of liposomes. The total cell count in bronchoalveolar lavage fluid did not differ significantly between groups I and II. However, in group III it decreased rapidly from 6.2 to 2.8 x 10(5) cells @entity4 within 2 h. Differential counts did not change in group I, but in group II a transient neutrophilia was observed 180 min after the instillation of liposomes. In group III, the instillation of @entity2 -containing liposomes depleted all neutrophils and lymphocytes after 4 h. No @entity3 was found in samples of lavage fluid from any of the groups at time 0. In group I, liposomes induced the production of 0.03 ng @entity4 of @entity3 in the 1 h sample only. In group II, @entity3 peaked to 1 ng @entity4 at 1 h and had decreased to 0.35 ng @entity4 by 3 h. In group III, @entity3 peaked at 1 h, but only reached a level of 0.1 ng @entity4 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: PC:PS liposomes induce a recruitment of neutrophils and the release of @entity3 in the lungs of XXXX sensitized with Saccharopolyspora rectivirgula.

answer: @entity0


abstract: Insulin-like growth factors (IGF), @entity5 and @entity6 , are small polypeptides involved in regulating cell proliferation, survival, differentiation, and transformation. IGF activities are mediated through binding and activation of @entity4 or @entity3 ( @entity3 ). The role of the @entity4 pathway in promoting @entity0 growth and survival is well documented. Overexpression of @entity6 and @entity3 is reported in multiple types of @entity0 and is proposed as a potential mechanism for @entity0 cells to develop resistance to @entity4 -targeting therapy. MEDI-573 is a fully human antibody that neutralizes both @entity5 and @entity6 and inhibits IGF signaling through both the @entity4 and @entity3 pathways. Here, we show that MEDI-573 blocks the binding of @entity5 and @entity6 to @entity4 or @entity3 , leading to the inhibition of IGF-induced signaling pathways and cell proliferation. MEDI-573 significantly inhibited the in vivo growth of @entity5 - or @entity6 -driven @entity0 . Pharmacodynamic analysis demonstrated inhibition of @entity4 phosphorylation in @entity0 in @entity1 dosed with MEDI-573, indicating that the antitumor activity is mediated via inhibition of @entity4 signaling pathways. Finally, MEDI-573 significantly decreased @entity2 ( @entity2 ) uptake in IGF-driven @entity0 models, highlighting the potential utility of @entity2 -PET as a noninvasive pharmacodynamic readout for evaluating the use of MEDI-573 in the clinic. Taken together, these results demonstrate that the inhibition of @entity5 and @entity6 ligands by MEDI-573 results in potent antitumor activity and offers an effective approach to selectively target both the @entity4 and @entity3 signaling pathways.

title: Dual XXXX /II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and @entity0 growth.

answer: @entity5


abstract: Insulin-like growth factors (IGF), @entity5 and @entity6 , are small polypeptides involved in regulating cell proliferation, survival, differentiation, and transformation. IGF activities are mediated through binding and activation of @entity4 or @entity3 ( @entity3 ). The role of the @entity4 pathway in promoting @entity0 growth and survival is well documented. Overexpression of @entity6 and @entity3 is reported in multiple types of @entity0 and is proposed as a potential mechanism for @entity0 cells to develop resistance to @entity4 -targeting therapy. MEDI-573 is a fully human antibody that neutralizes both @entity5 and @entity6 and inhibits IGF signaling through both the @entity4 and @entity3 pathways. Here, we show that MEDI-573 blocks the binding of @entity5 and @entity6 to @entity4 or @entity3 , leading to the inhibition of IGF-induced signaling pathways and cell proliferation. MEDI-573 significantly inhibited the in vivo growth of @entity5 - or @entity6 -driven @entity0 . Pharmacodynamic analysis demonstrated inhibition of @entity4 phosphorylation in @entity0 in @entity1 dosed with MEDI-573, indicating that the antitumor activity is mediated via inhibition of @entity4 signaling pathways. Finally, MEDI-573 significantly decreased @entity2 ( @entity2 ) uptake in IGF-driven @entity0 models, highlighting the potential utility of @entity2 -PET as a noninvasive pharmacodynamic readout for evaluating the use of MEDI-573 in the clinic. Taken together, these results demonstrate that the inhibition of @entity5 and @entity6 ligands by MEDI-573 results in potent antitumor activity and offers an effective approach to selectively target both the @entity4 and @entity3 signaling pathways.

title: Dual @entity5 /II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and XXXX growth.

answer: @entity0


abstract: BACKGROUND: Incidence rates of renal replacement therapy (RRT) for @entity1 vary considerably worldwide. This study examines the independent association between the general population, health care system and renal service characteristics and RRT incidence rates. METHODS: RRT incidence data (2003-2005) were obtained from renal registries; general population age and health and macroeconomic indices were collected from secondary sources. Renal service organization and resource data were obtained through interviews and questionnaires. Linear regression models were built to establish the factors independently associated with RRT incidence, stratified by the @entity0 Development Index where required. False discovery rate (FDR) correction was adjusted for multiple testing. RESULTS: Across the 46 countries (population 1.25 billion), RRT incidence rates ranged from 12 to 455 (median 130) per million population. Gross domestic product ( @entity2 ) per capita [incidence rate ratio (IRR): 1.02 per  1000 increase, P(FDR) = 0.047], percentage of @entity2 spent on health care (IRR: 1.11 per % increase, P(FDR) = 0.006) and dialysis facility reimbursement rate relative to @entity2 (IRR: 0.76 per @entity2 per capita-sized increase in reimbursement rate, P(FDR) = 0.007) were independently associated with RRT incidence. In more developed countries, the private for-profit share of haemodialysis facilities was also associated with higher incidence (IRR: 1.009 per % increase, P(FDR) = 0.003). CONCLUSIONS: Macroeconomic and renal service factors are more often associated with RRT incidence rates than measured demographic or general population health status factors.

title: Global variation in renal replacement therapy for XXXX .

answer: @entity1


abstract: Regulation of the activity of @entity1 of Streptococcus sp. (group K) was evaluated by examining the effects of @entity3 on the hydrolysis of colominic acids catalyzed by the @entity1 . Two kinds of @entity0 binding site, activation and inhibition sites, were proposed to exist. Competitive inhibition was observed with @entity3 smaller than @entity2 #300 (average molecular weight: 300), so the inhibition site is considered to be the substrate binding site, the size of which was estimated to be 10 A in diameter. On the contrary, @entity2 larger than this size activated the enzyme by 1.5-1.8 times. The activity could be raised by binding of the @entity2 to the activation site. This activation was shown to be due solely to the decrease in the Michaelis constant, Km. The smaller @entity2 (#200 and #300) were also considered to bind to the activation site, although activation was not clearly observed due to compensation with inhibition. Strong substrate inhibition by @entity4 was also observed. The activity of Streptococcus @entity1 was shown to be regulated intricately by the substrate @entity4 and @entity3 contained in the reaction medium.

title: Effects of @entity3 on the hydrolysis of @entity4 catalyzed by Streptococcus XXXX .

answer: @entity1


abstract: Regulation of the activity of @entity1 of Streptococcus sp. (group K) was evaluated by examining the effects of @entity3 on the hydrolysis of colominic acids catalyzed by the @entity1 . Two kinds of @entity0 binding site, activation and inhibition sites, were proposed to exist. Competitive inhibition was observed with @entity3 smaller than @entity2 #300 (average molecular weight: 300), so the inhibition site is considered to be the substrate binding site, the size of which was estimated to be 10 A in diameter. On the contrary, @entity2 larger than this size activated the enzyme by 1.5-1.8 times. The activity could be raised by binding of the @entity2 to the activation site. This activation was shown to be due solely to the decrease in the Michaelis constant, Km. The smaller @entity2 (#200 and #300) were also considered to bind to the activation site, although activation was not clearly observed due to compensation with inhibition. Strong substrate inhibition by @entity4 was also observed. The activity of Streptococcus @entity1 was shown to be regulated intricately by the substrate @entity4 and @entity3 contained in the reaction medium.

title: Effects of XXXX on the hydrolysis of @entity4 catalyzed by Streptococcus @entity1 .

answer: @entity3


abstract: Regulation of the activity of @entity1 of Streptococcus sp. (group K) was evaluated by examining the effects of @entity3 on the hydrolysis of colominic acids catalyzed by the @entity1 . Two kinds of @entity0 binding site, activation and inhibition sites, were proposed to exist. Competitive inhibition was observed with @entity3 smaller than @entity2 #300 (average molecular weight: 300), so the inhibition site is considered to be the substrate binding site, the size of which was estimated to be 10 A in diameter. On the contrary, @entity2 larger than this size activated the enzyme by 1.5-1.8 times. The activity could be raised by binding of the @entity2 to the activation site. This activation was shown to be due solely to the decrease in the Michaelis constant, Km. The smaller @entity2 (#200 and #300) were also considered to bind to the activation site, although activation was not clearly observed due to compensation with inhibition. Strong substrate inhibition by @entity4 was also observed. The activity of Streptococcus @entity1 was shown to be regulated intricately by the substrate @entity4 and @entity3 contained in the reaction medium.

title: Effects of @entity3 on the hydrolysis of XXXX catalyzed by Streptococcus @entity1 .

answer: @entity4


abstract: Evidence so far indicates two sources for excess mortality in @entity4 --suicide and @entity1 . The risk for eventual suicide may rival that for primary @entity2 , but the predictors and the necessary antecedents probably differ. The lapse between diagnosis and suicide may be larger for @entity4 , and complications such as secondary @entity2 and @entity3 may be necessary. There are few well-established predictors for primary @entity2 despite many relevant studies. The risk for suicide in @entity4 is barely recognized, and established predictors are accordingly remote. One study has demonstrated excess @entity1 among males with @entity4 , and another from the same center has provided weak support. Only one additional study has provided the necessary detail as to sex and cause, and those findings were quite supportive, although the subjects may have been mixed diagnostically. There are numerous feasible explanations for excess @entity1 in @entity4 and even some reason to believe that successful treatment might lessen it. To so advise @entity0 would be not only premature at this point but unnecessary and countertherapeutic--unnecessary because these @entity0 are motivated by discomfort to seek treatment and countertherapeutic because @entity1 is what many of these @entity0 pathologically fear. Rather, the findings suggest focus for future study. The initial findings of excess @entity1 in males badly need replication, as do the more recent findings of Kahn et al. Likewise, animal models may reveal some of the pathophysiologic mechanisms at work. It is hoped that these efforts will converge in the not-too-distant future.

title: XXXX and mortality.

answer: @entity4


abstract: The following results can be derived from the clinical and radiobiological literature as well as from the authors's own experiences with 91 @entity0 analyzed retrospectively and evaluated with respect to their risk factors. 1. A postoperative irradiation is very probably sensible in @entity0 with @entity2 perforation through the renal capsule (T3/T4) and with venous or lymph node manifestations. 2. The operation method is essential, above all the transabdominal technique and the quality of lymph dissection. 3. Prospective studies are necessary in order to clear up the role of radiotherapy in @entity0 with lymph node manifestations and the other two risk factors mentioned in item 1. 4. Further studies on the @entity2 biology of the @entity3 are necessary in order to gain prognostic criteria allowing a pretherapeutic sensitivity recognition. 5. The effect of a supplementary radiotherapy can be only that of local recurrence prevention in case of a locally advanced @entity2 and the absence of demonstrable remote @entity1 . This seems justified, because the local recurrence rate in our own @entity0 was only 3.3%.

title: [The role of postoperative radiotherapy in the treatment of XXXX ].

answer: @entity3


abstract: To investigate the role of phosphorylation and dephosphorylation in modulating the activity and location of @entity0 : @entity3 cytidylyltransferase, we used site-directed mutagenesis to construct four mutant forms of cytidylyltransferase. These forms were 5SP-->AP, in which five of the seven Ser-Pro sequences were converted to @entity6 ; @entity7 , in which all of the seven Ser-Pro sequences converted to @entity6 ; @entity8 , in which all sixteen Ser residues that can be phosphorylated in wild type cytidylyltransferase were converted to Ala; and @entity9 , in which all sixteen Ser residues were converted to @entity1 . The mutant enzymes were expressed in the strain 58 @entity4 ovary cell line, which is temperature-sensitive for growth and cytidylyltransferase activity. All mutant enzyme forms were enzymatically as active as the wild type when assayed under optimal conditions. In untreated cells, more of the @entity5 mutants were membrane-associated than in cells expressing wild type enzyme, consistent with the phosphorylation state of the enzyme affecting its affinity for membranes. About half of the @entity8 mutant remained soluble, however, indicating that dephosphorylation alone does not trigger membrane association. Although the amount of membrane-associated enzyme in the @entity8 mutant was about 10-fold greater than that of wild type, @entity2 synthesis was increased by only about 75%, suggesting that membrane association does not necessarily cause full activation. All mutant forms, including the @entity9 mutant, translocated to the particulate fraction upon oleate treatment, indicating that a high negative charge in the phosphorylation region does not preclude association of cytidylyltransferase with membranes. All mutant enzymes were able to support growth of strain 58 at 40 degrees C, and the rate of @entity2 synthesis was not greatly altered in the cell lines expressing mutant cytidylyltransferase forms. These results are consistent with a role for phosphorylation in the equilibrium distribution of cytidylyltransferase but suggest that changes in enzyme activity and location are not triggered exclusively by changes in the phosphorylation state.

title: Effects of altered phosphorylation sites on the properties of @entity0 : XXXX cytidylyltransferase.

answer: @entity3


abstract: To investigate the role of phosphorylation and dephosphorylation in modulating the activity and location of @entity0 : @entity3 cytidylyltransferase, we used site-directed mutagenesis to construct four mutant forms of cytidylyltransferase. These forms were 5SP-->AP, in which five of the seven Ser-Pro sequences were converted to @entity6 ; @entity7 , in which all of the seven Ser-Pro sequences converted to @entity6 ; @entity8 , in which all sixteen Ser residues that can be phosphorylated in wild type cytidylyltransferase were converted to Ala; and @entity9 , in which all sixteen Ser residues were converted to @entity1 . The mutant enzymes were expressed in the strain 58 @entity4 ovary cell line, which is temperature-sensitive for growth and cytidylyltransferase activity. All mutant enzyme forms were enzymatically as active as the wild type when assayed under optimal conditions. In untreated cells, more of the @entity5 mutants were membrane-associated than in cells expressing wild type enzyme, consistent with the phosphorylation state of the enzyme affecting its affinity for membranes. About half of the @entity8 mutant remained soluble, however, indicating that dephosphorylation alone does not trigger membrane association. Although the amount of membrane-associated enzyme in the @entity8 mutant was about 10-fold greater than that of wild type, @entity2 synthesis was increased by only about 75%, suggesting that membrane association does not necessarily cause full activation. All mutant forms, including the @entity9 mutant, translocated to the particulate fraction upon oleate treatment, indicating that a high negative charge in the phosphorylation region does not preclude association of cytidylyltransferase with membranes. All mutant enzymes were able to support growth of strain 58 at 40 degrees C, and the rate of @entity2 synthesis was not greatly altered in the cell lines expressing mutant cytidylyltransferase forms. These results are consistent with a role for phosphorylation in the equilibrium distribution of cytidylyltransferase but suggest that changes in enzyme activity and location are not triggered exclusively by changes in the phosphorylation state.

title: Effects of altered phosphorylation sites on the properties of XXXX : @entity3 cytidylyltransferase.

answer: @entity0


abstract: PURPOSE: Infections of the lower respiratory tract pose an important problem in nursing homes. Despite the magnitude of this problem, few, if any, antibiotic studies have been targeted specifically at nursing home-acquired @entity2 . Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of @entity2 , a comparative trial of oral @entity5 and intramuscular @entity7 was initiated in elderly @entity0 with lower @entity4 . In addition to assessing the relative efficacy and safety of @entity5 and @entity7 , our goals were to identify problems and pitfalls associated with conducting clinical research in this nursing home setting, evaluate selected clinical and laboratory features of lower respiratory tract @entity2 in this @entity0 population, and measure outcomes in all study groups. @entity0 AND METHODS: During a 20-month period, 40 @entity0 with @entity1 and 20 @entity0 with acute @entity6 were enrolled in this randomized study. Sixty-three @entity0 with @entity1 who were ineligible for the randomized study were also followed prospectively. The mean age of the 111 @entity0 (123 cases) was 80.8 years; all @entity0 had at least one chronic medical condition. RESULTS: Although @entity3 was the single most common isolate, gram-negative bacteria were cultured from 81 percent of the cases that yielded pathogens from a satisfactory sputum specimen. The in-hospital mortality rate was strikingly low (6.5 percent), and a large majority of @entity0 in all study groups were discharged safely back to their nursing homes well within the Diagnosis-Related Group length of stay. CONCLUSION: @entity5 appeared to be as safe and effective as @entity7 in this nursing home program; however, additional studies are needed to determine its role in the treatment of elderly @entity0 with @entity2 .

title: Prospective study of lower XXXX in an extended-care nursing home program: potential role of oral @entity5 .

answer: @entity4


abstract: PURPOSE: Infections of the lower respiratory tract pose an important problem in nursing homes. Despite the magnitude of this problem, few, if any, antibiotic studies have been targeted specifically at nursing home-acquired @entity2 . Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of @entity2 , a comparative trial of oral @entity5 and intramuscular @entity7 was initiated in elderly @entity0 with lower @entity4 . In addition to assessing the relative efficacy and safety of @entity5 and @entity7 , our goals were to identify problems and pitfalls associated with conducting clinical research in this nursing home setting, evaluate selected clinical and laboratory features of lower respiratory tract @entity2 in this @entity0 population, and measure outcomes in all study groups. @entity0 AND METHODS: During a 20-month period, 40 @entity0 with @entity1 and 20 @entity0 with acute @entity6 were enrolled in this randomized study. Sixty-three @entity0 with @entity1 who were ineligible for the randomized study were also followed prospectively. The mean age of the 111 @entity0 (123 cases) was 80.8 years; all @entity0 had at least one chronic medical condition. RESULTS: Although @entity3 was the single most common isolate, gram-negative bacteria were cultured from 81 percent of the cases that yielded pathogens from a satisfactory sputum specimen. The in-hospital mortality rate was strikingly low (6.5 percent), and a large majority of @entity0 in all study groups were discharged safely back to their nursing homes well within the Diagnosis-Related Group length of stay. CONCLUSION: @entity5 appeared to be as safe and effective as @entity7 in this nursing home program; however, additional studies are needed to determine its role in the treatment of elderly @entity0 with @entity2 .

title: Prospective study of lower @entity4 in an extended-care nursing home program: potential role of oral XXXX .

answer: @entity5


abstract: Resection of @entity6 can be difficult to perform because of its site, vascularity, arterial adherence and local cranial nerve involvement. Advances in vascular surgical technique have reduced the risks of perioperative complications such as @entity3 , @entity2 and @entity4 . From January 1980 to May 1994 20 @entity0 (22 @entity6 ) were examined. All @entity0 except one were evaluated with a preoperative angiography. No preoperative embolization was performed. Thirteen @entity0 underwent ultrasonography, nine a CT scan of the neck, 5 magnetic resonance scanning and two magnetic resonance angiography. One old @entity0 refused operation. The authors report their experience on 21 carotid body @entity1 resections (14 Shamblin group I and 7 group II @entity5 ). Surgical technique is based on subadventitial resection (18 excisions) and 3 resections were performed from the medial surface of the carotid bifurcation which had been partially absorbed into the mass. In the last 15 operations intraoperative Somatosensorial Evoked Potential (SEP) monitoring has been used. Only two @entity0 required arterial repair because intimal dissection and another @entity0 needed vagus nerve section. The ligation of external carotid artery and internal carotid resection with graft replacement were never necessary in these @entity0 . No early or late @entity4 occurred and no recurrences were detected at follow-up.

title: Diagnosis and surgical treatment of the XXXX .

answer: @entity6


abstract: The osteogenic growth peptide (OGP) was recently characterized in regenerating bone marrow. In experimental animals, OGP increases osteogenesis. Immunoreactive OGP (irOGP) in high abundance was demonstrated in normal animal serum mainly as an OGP-OGP-binding protein (OGPBP) complex. Here we show the presence of an OGP-OGPBP system in normal human serum. The total irOGP content, of which the bound peptide comprises at least 80-90%, ranged from 480-4460 mumol/L, several orders of magnitude higher than that of other regulatory polypeptides. The steady state/total irOGP ratio declined between 23 and 49 yr of age. The bound irOGP, purified by boiling, ultrafiltration, and hydrophobic high pressure liquid chromatography, was identical to OGP obtained previously from @entity2 regenerating marrow and @entity1 stromal cell cultures in terms of its @entity4 sequence, immunoreactivity, and mitogenicity. These data demonstrate the usefulness of our immunoassay to measure circulating OGP. More importantly, the identity of the @entity0 OGP with that of other species indicates the peptide's evolutionary conservation and, thus, its biological importance. The natural occurrence of OGP in @entity0 signifies its potential role in the prevention of @entity5 and rescue of bone mass, especially in @entity3 .

title: Structural and functional characterization of osteogenic growth peptide from human serum: identity with XXXX and @entity1 homologs.

answer: @entity2


abstract: The osteogenic growth peptide (OGP) was recently characterized in regenerating bone marrow. In experimental animals, OGP increases osteogenesis. Immunoreactive OGP (irOGP) in high abundance was demonstrated in normal animal serum mainly as an OGP-OGP-binding protein (OGPBP) complex. Here we show the presence of an OGP-OGPBP system in normal human serum. The total irOGP content, of which the bound peptide comprises at least 80-90%, ranged from 480-4460 mumol/L, several orders of magnitude higher than that of other regulatory polypeptides. The steady state/total irOGP ratio declined between 23 and 49 yr of age. The bound irOGP, purified by boiling, ultrafiltration, and hydrophobic high pressure liquid chromatography, was identical to OGP obtained previously from @entity2 regenerating marrow and @entity1 stromal cell cultures in terms of its @entity4 sequence, immunoreactivity, and mitogenicity. These data demonstrate the usefulness of our immunoassay to measure circulating OGP. More importantly, the identity of the @entity0 OGP with that of other species indicates the peptide's evolutionary conservation and, thus, its biological importance. The natural occurrence of OGP in @entity0 signifies its potential role in the prevention of @entity5 and rescue of bone mass, especially in @entity3 .

title: Structural and functional characterization of osteogenic growth peptide from human serum: identity with @entity2 and XXXX homologs.

answer: @entity1


abstract: Therapeutic angiogenesis remains unsuccessful in @entity2 . It is known that plasma endothelium-derived microparticles (EMPs) are increased in @entity2 and that @entity5 can inhibit angiogenesis. We evaluated the relationship between EMPs and @entity5 in the impairment of angiogenesis. EMPs isolated from @entity0 umbilical vein endothelial cells were injected into @entity4 -null (LDLr(-/-)) @entity1 fed a Western diet for 2 wk and C57BL6 @entity1 for 6 h or were directly added to the tissue culture media. Hearts isolated from @entity1 were sectioned and cultured, and endothelial tube formation was measured. The expression and phosphorylation of endothelial NO synthase (eNOS) and the generation of NO in the hearts were determined. Angiogenesis was inhibited by pathophysiological concentrations of EMPs but not physiological concentrations of EMPs in hearts from C57BL6 @entity1 . However, angiogenesis was inhibited by EMPs at both physiological and pathophysiological concentrations of EMPs in hearts from @entity3 (-/-) @entity1 . Pathophysiological concentrations of EMPs decreased eNOS phosphorylation at Ser(1177) and NO generation without altering eNOS expression in hearts from C57BL6 @entity1 . Both physiological and pathophysiological concentrations of EMPs decreased not only eNOS phosphorylation at Ser(1177) and NO generation, but eNOS expression in @entity3 hearts from LDLr(-/-) @entity1 . These data demonstrated that pathophysiological concentrations of EMPs could inhibit angiogenesis in hearts by decreasing eNOS activity. EMPs and @entity5 mutually enhanced their inhibitory effect of angiogenesis by inducing eNOS dysfunction. Our findings suggest a novel mechanism by which @entity5 impairs angiogenesis.

title: Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of XXXX on angiogenesis.

answer: @entity5


abstract: BACKGROUND AND PURPOSE: The present study was performed to examine the potential of diffusion-weighted (DW) imaging and dynamic first-passage bolus tracking of susceptibility contrast agents (perfusion imaging) for early in vivo evaluation of the effects of treatment with the free radical scavenger U74389G in a @entity0 model of temporary focal @entity1 . METHODS: After 45 minutes of @entity2 , the treatment group (n = 9) received an infusion of U74389G, and the control group (n = 9) received the identical volume of the vehicle. Reperfusion was instituted in both groups after 120 minutes of @entity2 . The DW images were collected during @entity2 and reperfusion and were compared with histologically assessed areas of tissue injury after 2 hours of reperfusion. The dynamic perfusion series were processed on a pixel-to-pixel basis to produce parametric maps reflecting the maximum reduction in the signal obtained during the first passage of the contrast agent and the time delay between the arrival of the bolus and the point of maximum contrast-agent effect. RESULTS: The area of @entity1 , as assessed from the DW imaging at 60 minutes of reperfusion, was significantly smaller in the treatment group: 9 +/- 8% of ipsilateral hemisphere compared with 19 +/- 8% in the control group. The histological examination after 2 hours of reperfusion demonstrated an area of @entity1 of 10 +/- 8% for the treatment group compared to 25 +/- 10% in the control group. In the treatment group, the perfusion imaging showed a reduction in time delay to maximum effect of the contrast agent in the @entity1 hemisphere compared with the control group. CONCLUSIONS: The DW imaging during early reperfusion showed a protective effect of postocclusion treatment with the free radical scavenger U74389G. The improvement of time delay to maximum effect of the contrast agent observed in the perfusion imaging of the treatment group may reflect an improvement in the collateral flow to the @entity1 tissue.

title: Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a XXXX stroke model.

answer: @entity0


abstract: BACKGROUND: @entity4 as a presenting sign of @entity7 has been infrequently reported. We describe six @entity0 in whom @entity3 was the first manifestation of this @entity3 . A positive endogenous megakaryocyte and/or erythroid colony growth from blood was a diagnostic criterion of @entity7 in @entity0 with platelets counts lower than 600 x 10(9)/L. CASE DESCRIPTIONS: These six @entity0 represented 0.54% of all @entity0 with first @entity2 , 42.8% of all @entity6 associated with @entity2 , and 12.5% of all @entity0 with @entity7 diagnosed from 1986 to 1992 at our institution. Eleven @entity2 (6 transient @entity1 attacks, 5 definitive @entity4 ) were registered. Mean time from @entity4 to diagnosis of @entity7 was 4.5 months (range, 1 to 12 months). The mean platelet count was 597 x 10(9)/L (range, 414 to 760 x 10(9)/L). Four @entity0 had platelets counts lower than 600 x 10(9)/L. All @entity0 had circulating erythroid progenitors, megakaryocytic progenitors, or both. CONCLUSIONS: @entity4 as a presenting manifestation of @entity7 is probably underrecognized. The diagnosis of @entity5 should not be excluded on the basis of platelet counts lower than 600 x 10(9)/L. The availability of in vitro culture of hematopoietic progenitors from peripheral blood makes it possible to diagnose early and atypical cases.

title: XXXX as first manifestation of @entity7 . Report of six cases.

answer: @entity4


abstract: BACKGROUND: @entity4 as a presenting sign of @entity7 has been infrequently reported. We describe six @entity0 in whom @entity3 was the first manifestation of this @entity3 . A positive endogenous megakaryocyte and/or erythroid colony growth from blood was a diagnostic criterion of @entity7 in @entity0 with platelets counts lower than 600 x 10(9)/L. CASE DESCRIPTIONS: These six @entity0 represented 0.54% of all @entity0 with first @entity2 , 42.8% of all @entity6 associated with @entity2 , and 12.5% of all @entity0 with @entity7 diagnosed from 1986 to 1992 at our institution. Eleven @entity2 (6 transient @entity1 attacks, 5 definitive @entity4 ) were registered. Mean time from @entity4 to diagnosis of @entity7 was 4.5 months (range, 1 to 12 months). The mean platelet count was 597 x 10(9)/L (range, 414 to 760 x 10(9)/L). Four @entity0 had platelets counts lower than 600 x 10(9)/L. All @entity0 had circulating erythroid progenitors, megakaryocytic progenitors, or both. CONCLUSIONS: @entity4 as a presenting manifestation of @entity7 is probably underrecognized. The diagnosis of @entity5 should not be excluded on the basis of platelet counts lower than 600 x 10(9)/L. The availability of in vitro culture of hematopoietic progenitors from peripheral blood makes it possible to diagnose early and atypical cases.

title: @entity4 as first manifestation of XXXX . Report of six cases.

answer: @entity7


abstract: BACKGROUND: Catheter ablation is increasingly used to manage @entity6 , but @entity5 recurrences are common. @entity4 might identify pulmonary veins at risk of reconnection by unmasking dormant conduction, and thereby guide additional ablation to improve @entity5 -free survival. We assessed whether @entity4 -guided @entity3 could prevent @entity5 recurrence in @entity0 undergoing radiofrequency catheter ablation for @entity6 . METHODS: We did this randomised trial at 18 hospitals in Australia, Europe, and North America. We enrolled @entity0 aged older than 18 years who had had at least three symptomatic @entity6 episodes in the past 6 months, and for whom treatment with an antiarrhythmic drug failed. After @entity3 , intravenous @entity4 was administered. If dormant conduction was present, @entity0 were randomly assigned (1:1) to additional @entity4 -guided ablation to abolish dormant conduction or to no further ablation. If no dormant conduction was revealed, randomly selected @entity0 were included in a registry. @entity0 were masked to treatment allocation and outcomes were assessed by a masked adjudicating committee. @entity0 were followed up for 1 year. The primary outcome was time to symptomatic @entity7 after a single procedure in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01058980. FINDINGS: @entity4 unmasked dormant pulmonary vein conduction in 284 (53%) of 534 @entity0 . 102 (69  4%) of 147 @entity0 with additional @entity4 -guided ablation were free from symptomatic @entity7 compared with 58 (42  3%) of 137 @entity0 with no further ablation, corresponding to an absolute risk reduction of 27  1% (95% CI 15  9-38  2; p<0  0001) and a hazard ratio of 0  44 (95% CI 0  31-0  64; p<0  0001). Of 115 @entity0 without dormant pulmonary vein conduction, 64 (55  7%) remained free from symptomatic @entity7 (p=0  0191 vs dormant conduction with no further ablation). Occurrences of serious adverse events were similar in each group. One @entity2 (massive @entity1 ) was deemed probably related to ablation in a @entity0 included in the registry. INTERPRETATION: @entity4 testing to identify and target dormant pulmonary vein conduction during catheter ablation of @entity6 is a safe and highly effective strategy to improve @entity5 -free survival in @entity0 with @entity6 . This approach should be considered for incorporation into routine clinical practice. FUNDING: Canadian Institutes of Health Research, St Jude Medical, Biosense-Webster, and M Lachapelle (Montreal Heart Institute Foundation).

title: @entity4 -guided XXXX for the treatment of @entity6 : an international, multicentre, randomised superiority trial.

answer: @entity3


abstract: BACKGROUND: Catheter ablation is increasingly used to manage @entity6 , but @entity5 recurrences are common. @entity4 might identify pulmonary veins at risk of reconnection by unmasking dormant conduction, and thereby guide additional ablation to improve @entity5 -free survival. We assessed whether @entity4 -guided @entity3 could prevent @entity5 recurrence in @entity0 undergoing radiofrequency catheter ablation for @entity6 . METHODS: We did this randomised trial at 18 hospitals in Australia, Europe, and North America. We enrolled @entity0 aged older than 18 years who had had at least three symptomatic @entity6 episodes in the past 6 months, and for whom treatment with an antiarrhythmic drug failed. After @entity3 , intravenous @entity4 was administered. If dormant conduction was present, @entity0 were randomly assigned (1:1) to additional @entity4 -guided ablation to abolish dormant conduction or to no further ablation. If no dormant conduction was revealed, randomly selected @entity0 were included in a registry. @entity0 were masked to treatment allocation and outcomes were assessed by a masked adjudicating committee. @entity0 were followed up for 1 year. The primary outcome was time to symptomatic @entity7 after a single procedure in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01058980. FINDINGS: @entity4 unmasked dormant pulmonary vein conduction in 284 (53%) of 534 @entity0 . 102 (69  4%) of 147 @entity0 with additional @entity4 -guided ablation were free from symptomatic @entity7 compared with 58 (42  3%) of 137 @entity0 with no further ablation, corresponding to an absolute risk reduction of 27  1% (95% CI 15  9-38  2; p<0  0001) and a hazard ratio of 0  44 (95% CI 0  31-0  64; p<0  0001). Of 115 @entity0 without dormant pulmonary vein conduction, 64 (55  7%) remained free from symptomatic @entity7 (p=0  0191 vs dormant conduction with no further ablation). Occurrences of serious adverse events were similar in each group. One @entity2 (massive @entity1 ) was deemed probably related to ablation in a @entity0 included in the registry. INTERPRETATION: @entity4 testing to identify and target dormant pulmonary vein conduction during catheter ablation of @entity6 is a safe and highly effective strategy to improve @entity5 -free survival in @entity0 with @entity6 . This approach should be considered for incorporation into routine clinical practice. FUNDING: Canadian Institutes of Health Research, St Jude Medical, Biosense-Webster, and M Lachapelle (Montreal Heart Institute Foundation).

title: @entity4 -guided @entity3 for the treatment of XXXX : an international, multicentre, randomised superiority trial.

answer: @entity6


abstract: BACKGROUND: Catheter ablation is increasingly used to manage @entity6 , but @entity5 recurrences are common. @entity4 might identify pulmonary veins at risk of reconnection by unmasking dormant conduction, and thereby guide additional ablation to improve @entity5 -free survival. We assessed whether @entity4 -guided @entity3 could prevent @entity5 recurrence in @entity0 undergoing radiofrequency catheter ablation for @entity6 . METHODS: We did this randomised trial at 18 hospitals in Australia, Europe, and North America. We enrolled @entity0 aged older than 18 years who had had at least three symptomatic @entity6 episodes in the past 6 months, and for whom treatment with an antiarrhythmic drug failed. After @entity3 , intravenous @entity4 was administered. If dormant conduction was present, @entity0 were randomly assigned (1:1) to additional @entity4 -guided ablation to abolish dormant conduction or to no further ablation. If no dormant conduction was revealed, randomly selected @entity0 were included in a registry. @entity0 were masked to treatment allocation and outcomes were assessed by a masked adjudicating committee. @entity0 were followed up for 1 year. The primary outcome was time to symptomatic @entity7 after a single procedure in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01058980. FINDINGS: @entity4 unmasked dormant pulmonary vein conduction in 284 (53%) of 534 @entity0 . 102 (69  4%) of 147 @entity0 with additional @entity4 -guided ablation were free from symptomatic @entity7 compared with 58 (42  3%) of 137 @entity0 with no further ablation, corresponding to an absolute risk reduction of 27  1% (95% CI 15  9-38  2; p<0  0001) and a hazard ratio of 0  44 (95% CI 0  31-0  64; p<0  0001). Of 115 @entity0 without dormant pulmonary vein conduction, 64 (55  7%) remained free from symptomatic @entity7 (p=0  0191 vs dormant conduction with no further ablation). Occurrences of serious adverse events were similar in each group. One @entity2 (massive @entity1 ) was deemed probably related to ablation in a @entity0 included in the registry. INTERPRETATION: @entity4 testing to identify and target dormant pulmonary vein conduction during catheter ablation of @entity6 is a safe and highly effective strategy to improve @entity5 -free survival in @entity0 with @entity6 . This approach should be considered for incorporation into routine clinical practice. FUNDING: Canadian Institutes of Health Research, St Jude Medical, Biosense-Webster, and M Lachapelle (Montreal Heart Institute Foundation).

title: XXXX -guided @entity3 for the treatment of @entity6 : an international, multicentre, randomised superiority trial.

answer: @entity4


abstract: BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS: @entity0 with @entity2 treated with @entity3 or @entity7 in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with @entity1 , radiological response, and overall survival. RESULTS: 52 @entity0 were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of a-fetoprotein of 29,554  85,654ng/mL, with a median overall survival of 10.5 months. @entity5 was associated with a greater rate of @entity6 (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of @entity6 and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of @entity6 (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to @entity4 kinase inhibitors in @entity0 with @entity2 .

title: Visceral fat area predicts survival in @entity0 with @entity2 treated with XXXX kinase inhibitors.

answer: @entity4


abstract: BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS: @entity0 with @entity2 treated with @entity3 or @entity7 in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with @entity1 , radiological response, and overall survival. RESULTS: 52 @entity0 were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of a-fetoprotein of 29,554  85,654ng/mL, with a median overall survival of 10.5 months. @entity5 was associated with a greater rate of @entity6 (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of @entity6 and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of @entity6 (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to @entity4 kinase inhibitors in @entity0 with @entity2 .

title: Visceral fat area predicts survival in @entity0 with XXXX treated with @entity4 kinase inhibitors.

answer: @entity2


abstract: BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS: @entity0 with @entity2 treated with @entity3 or @entity7 in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with @entity1 , radiological response, and overall survival. RESULTS: 52 @entity0 were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of a-fetoprotein of 29,554  85,654ng/mL, with a median overall survival of 10.5 months. @entity5 was associated with a greater rate of @entity6 (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of @entity6 and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of @entity6 (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to @entity4 kinase inhibitors in @entity0 with @entity2 .

title: Visceral fat area predicts survival in XXXX with @entity2 treated with @entity4 kinase inhibitors.

answer: @entity0


abstract: BACKGROUND/PURPOSE: Partial splenectomy has emerged as a surgical option for selected @entity0 with @entity5 , with the goal of reducing @entity2 while preserving splenic function. This multi-institutional study is the largest series to date examining outcomes data for partial splenectomy in @entity0 with @entity5 . METHODS: Data were collected retrospectively from 5 North American pediatric hospitals. Sixty-two @entity0 underwent partial splenectomy for @entity5 between 1990 and 2008. RESULTS: At 1 year following partial splenectomy, mean hemoglobin significantly increased by 3.0    1.4 g/dL (n = 52), reticulocyte count decreased by 6.6%    6.6% (n = 41), and @entity4 level decreased by 1.3    0.9 mg/dL (n = 25). @entity0 with poor or transient hematologic response were found to have significantly more splenic regeneration postoperatively compared with @entity0 with a durable clinical response (maximal spleen dimension, 9.0    3.4 vs 6.3    2.2 cm). Clinically significant recurrence of @entity2 or @entity3 led to completion splenectomy in 4.84% of @entity0 . No @entity0 developed @entity1 . CONCLUSIONS: Our multi-institutional review indicates that partial splenectomy for @entity5 leads to sustained and clinically significant improvement in hematologic profiles and clinical symptoms in most @entity0 . Our data support partial splenectomy as an alternative for selected @entity0 with @entity5 .

title: Partial splenectomy for XXXX : a multi-institutional review.

answer: @entity5


abstract: OBJECTIVE: Test with an @entity3 ( @entity3 ) to assess whether an unpreserved cadaver @entity1 training course, including upper and lower limb vascular exposure, improves correct identification of surgical landmarks, underlying anatomy, and shortens time to vascular control. DESIGN: Prospective study of performance of 3 vascular exposure and control procedures (axillary, brachial, and femoral arteries) using @entity3 metrics by 2 colocated and trained evaluators before and after training with the Advanced Surgical Skills Exposure for @entity1 (ASSET) course. @entity3 , including identification of anatomical landmarks, incisions, underlying structures, and time to completion of each procedure was compared before and after training using repeated measurement models. SETTING: Audio-video instrumented cadaver laboratory at University of Maryland School of Medicine. @entity0 : A total of 41 second to sixth year surgical residents from surgical programs throughout Mid-Atlantic States who had not previously taken the ASSET course were enrolled, 40 completed the pre- and post-ASSET performance evaluations. RESULTS: After ASSET training, all components of @entity3 increased and time shortened for each of the 3 artery exposures. Procedure steps performed correctly increased 57%, anatomical knowledge increased 43% and skin incision to passage of a vessel loop twice around the correct vessel decreased by a mean of 2.5 minutes. An overall vascular @entity1 readiness index, a comprehensive @entity3 score for 3 procedures increased 28% with ASSET Training. CONCLUSIONS: Improved knowledge of surface landmarks and underlying anatomy is associated with increased @entity3 , faster procedures, more accurate incision placement, and successful vascular control. Structural recognition during specific procedural steps and anatomical knowledge were key points learned during the ASSET course. Such training may accelerate acquisition of specific @entity1 surgery skills to compensate for shortened training hours, infrequent exposure to major @entity2 , or when just-in-time training is necessary. @entity3 is a benchmark for competence in extremity vascular control.

title: Using an Individual Procedure Score Before and After the Advanced Surgical Skills Exposure for XXXX Course Training to Benchmark a Hemorrhage-Control Performance Metric.

answer: @entity1


abstract: PURPOSE: High intensity focused ultrasound for the treatment of primary @entity3 is increasing in a subset of @entity0 seeking definitive treatment with reduced morbidity. We review outcomes in @entity0 undergoing salvage radical prostatectomy after failed whole gland high intensity focused ultrasound. MATERIALS AND METHODS: Prospective data were collected for @entity0 presenting with an increasing @entity4 and biopsy proven @entity3 after high intensity focused ultrasound from 2007 to 2010 who underwent salvage open radical prostatectomy with a 22-month median followup, including @entity4 , prostate volume, pathology results, continence and erectile function. RESULTS: Data for 15 @entity0 were available, including median age 64 years (IQR 55-69), Gleason score before high intensity focused ultrasound of 6 (8), Gleason score 7 (7), median cores positive 39% (IQR 17%-63%) and median @entity4 7 ng/ml (IQR 5-8). Whole gland high intensity focused ultrasound achieved median nadir @entity4 1.1 ng/ml (IQR 0.5-3.1). Biopsy after high intensity focused ultrasound demonstrated Gleason score 6 (in 3 @entity0 ), 7 (9) and 8/9 (3), and 42% (IQR 25%-50%) cores positive and a median time from high intensity focused ultrasound to radical prostatectomy of 22 months (IQR 7-26). Perioperative morbidity was limited to 1 transfusion in a @entity0 with a @entity2 . Pathologically extensive @entity1 was found with persistent @entity3 , as pT3 disease (in 9 of 14), Gleason scores 6 (2), 7 (9) and 8 of 9 (4), with focally positive margins in 3 of 11 (pT3a). Postoperative @entity4 was unrecordable in 14 of 15 @entity0 with further treatment in 2. Postoperative continence (more than 12 months of followup) yielded no pad use in 6 of 10 @entity0 with universally poor erectile function. CONCLUSIONS: Radical prostatectomy as salvage is feasible for @entity0 in whom high intensity focused ultrasound failed, but with a higher morbidity than for primary surgery. Pathology results are alarming given the number of cases with extraprostatic extension yet early followup data suggest acceptable oncologic control. These results should be factored in when counseling @entity0 who wish to undergo primary high intensity focused ultrasound.

title: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of XXXX .

answer: @entity3


abstract: BACKGROUND: Recent literature demonstrates a lower incidence of @entity7 with breast reconstruction. This study compared the incidence of @entity7 after axillary dissection in a propensity-matched cohort of @entity1 with and without immediate breast reconstruction. METHODS: A review of @entity1 undergoing axillary lymphadenectomy with or without immediate breast reconstruction from January 1, 2000, to July 1, 2013, was conducted. Comorbidities, @entity2 treatment, operative characteristics, and pathologic findings were reviewed. The primary outcome was @entity5 . Univariate analysis identified baseline differences between the @entity1 groups. Cohorts were propensity-matched by age, body mass index greater than 30 kg/m, adjuvant radiation therapy, @entity4 , and @entity6 . Subsequent multivariate regression was performed to identify independent predictors of @entity7 among matched @entity1 . RESULTS: A total of 4647 @entity1 underwent @entity0 resection, with 1955 having axillary lymphadenectomy (no reconstruction, n = 1200; autologous, n = 563; implant-based, n = 192). Matching yielded a cohort of 239 reconstruction and 239 no-reconstruction @entity1 demonstrating no differences in age, body mass index, @entity6 , adjuvant radiation therapy, or axillary dissection extent. With 55.9 months' follow-up, @entity5 was diagnosed in 94 @entity1 (19.7 percent). Reconstruction @entity1 developed @entity7 in 19.2 percent of cases versus 20.1 percent for no- reconstruction @entity1 (p = 0.82). Regression identified two independent predictors of @entity7 : postoperative radiation therapy (OR, 2.90; p < 0.001) and @entity3 (OR, 2.36; p < 0.001). CONCLUSIONS: This study demonstrates a 19.7 percent incidence of @entity7 following axillary lymphadenectomy. Reconstruction does not appear to alter @entity7 risk, whereas postoperative radiation therapy, @entity3 , and extensive axillary dissection greatly increase risk. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

title: A Propensity-Matched Analysis of the Influence of Breast Reconstruction on Subsequent Development of XXXX .

answer: @entity7


abstract: OBJECTIVE: To evaluate intermediate-term oncologic and renal functional outcome of laparoendoscopic single-site radical nephrectomy (LESS-RN) in the treatment of localized @entity4 . METHODS: We performed a chart review of @entity0 who underwent LESS-RN between 2009 and 2011 at our institution. @entity0 with a minimum of 3 years of follow-up were included in this study. The demographic data and main perioperative outcome variables were analyzed. Estimated glomerular filtration rate was calculated using the Modification of Diet @entity3 equation. @entity5 ( @entity5 ) was calculated. The Kaplan-Meier method was used to calculate overall survival (OS), @entity2 -specific survival (CSS), and @entity2 ( @entity2 ). Multivariate logistic regression was performed to show predicting factors for an undesirable outcome arbitrarily defined as any one or more of the following events: surgical conversion, complication of Clavien grade >2, new onset of @entity5 stages >= 3 at the latest follow-up, or @entity2 recurrence or @entity1 . RESULTS: A total of 51 @entity0 were included with a median follow-up of 41 (interquartile range: 38-45) months. The OS, CSS, and @entity2 rates at 3 years were 100%, 100%, and 98%, respectively. There was a 74.5% (38/51) upstaging of @entity5 at the latest follow-up, with 22 @entity0 (43.1%) who developed a new onset of @entity5 stages >= 3. Multivariate analysis showed that @entity0 age, body mass index, Charlson comorbidity index, early surgeon experience, and follow-up duration (all p   <   0.05) have increased the odds of an undesirable outcome. CONCLUSIONS: For localized @entity4 , LESS-RN is effective in oncologic control at an intermediate follow-up interval but, similar to other kinds of RN technique, it is associated with worsened renal functional outcomes.

title: Oncologic and Functional Outcomes of Laparoendoscopic Single-Site Radical Nephrectomy for Localized XXXX : A Single Surgeon's Series with a Minimum of 3-Year Follow-Up.

answer: @entity4


abstract: The important questions to be answered in the course of decision-making in @entity0 with @entity3 include the following: 1. Is the eye problem owing to @entity3 ? If not, the cause of the eye problem must be sought. 2. Does the @entity0 have serious medical problems apart from the thyroid and the eyes? Define type and severity, and risk to life and well-being. Do they preclude anesthesia or @entity1 therapy? 3. Is the @entity0 euthyroid? @entity2 and treat. 4. Is the eye problem the highest medical priority for the @entity0 and the physician? If not, treat the highest priority, then return to the eyes. 5. Which particular manifestations of @entity3 are the most troublesome to the @entity0 ? Establish priorities according to need and rational order for surgical procedures. 6. How have the eyes been treated in the past? What has been successful? What side effects have resulted? In the evaluation of a @entity0 with possible @entity3 , no single clinical or laboratory feature is necessary or pathognomonic of the disorder. The sufficient findings for a diagnosis are a matter of clinical judgment. Several diagnostic tools including CT scanning, various ophthalmologic examinations, and studies of thyroid function are available. The physician must use these tools, along with clinical judgment, to establish the diagnosis with maximum certainty. Following this, the particular manifestations of the disease that are most troublesome to the @entity0 must be carefully defined and assessed. Only then can the treatment be optimally tailored to the @entity0 's needs.

title: Diagnostic evaluation of XXXX .

answer: @entity3


abstract: OBJECTIVE: Offspring of parents with @entity2 ( @entity2 ) have been shown to be at high risk for @entity2 . @entity1 , even at subclinical levels, have been associated with increased risk for @entity2 in these youth. The s-allele of the @entity3 transporter-linked polymorphic region (5-HTTLPR) has been implicated in the pathophysiology of both @entity2 and @entity1 and has been associated with pharmacological treatment response and increased risk for antidepressant side effects. Therefore, we aimed to explore 1) whether @entity1 in offspring of @entity2 parents were associated with presence of the 5-HTTLPR s-allele and 2) whether @entity1 in the offspring of @entity2 parents according to the 5-HTTLPR genotypes are related to antianxiety medication status. METHODS: A total of 64 offspring of @entity2 parents (mean age: 13.7 years) and 51 healthy controls (HC) (mean age: 13.7 years) were compared genetically and on the Multidimensional @entity1 Scale for @entity0 (MASC). RESULTS: Offspring of @entity2 parents showed higher levels of overall @entity1 than did the HC group. Only antianxiety medication na  ve offspring of @entity2 parents were found to have an association between 5-HTTLPR genotypes and @entity1 . The antianxiety medication na  ve offspring of @entity2 parents with the s-allele showed higher level of overall @entity1 than offspring of @entity2 parents with the l/l genotype. No significant differences in @entity1 or their association with the 5-HTTLPR genotype were found in the HC group. CONCLUSIONS: This study indicated that there may be an association between 5-HTTLPR genotypes and @entity1 in offspring of @entity2 parents, and that antianxiety medication status may affect @entity1 in the offspring of @entity2 @entity0 according to genotype.

title: Association of XXXX Symptoms in Offspring of Bipolar Parents with @entity3 Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype.

answer: @entity1


abstract: OBJECTIVE: Offspring of parents with @entity2 ( @entity2 ) have been shown to be at high risk for @entity2 . @entity1 , even at subclinical levels, have been associated with increased risk for @entity2 in these youth. The s-allele of the @entity3 transporter-linked polymorphic region (5-HTTLPR) has been implicated in the pathophysiology of both @entity2 and @entity1 and has been associated with pharmacological treatment response and increased risk for antidepressant side effects. Therefore, we aimed to explore 1) whether @entity1 in offspring of @entity2 parents were associated with presence of the 5-HTTLPR s-allele and 2) whether @entity1 in the offspring of @entity2 parents according to the 5-HTTLPR genotypes are related to antianxiety medication status. METHODS: A total of 64 offspring of @entity2 parents (mean age: 13.7 years) and 51 healthy controls (HC) (mean age: 13.7 years) were compared genetically and on the Multidimensional @entity1 Scale for @entity0 (MASC). RESULTS: Offspring of @entity2 parents showed higher levels of overall @entity1 than did the HC group. Only antianxiety medication na  ve offspring of @entity2 parents were found to have an association between 5-HTTLPR genotypes and @entity1 . The antianxiety medication na  ve offspring of @entity2 parents with the s-allele showed higher level of overall @entity1 than offspring of @entity2 parents with the l/l genotype. No significant differences in @entity1 or their association with the 5-HTTLPR genotype were found in the HC group. CONCLUSIONS: This study indicated that there may be an association between 5-HTTLPR genotypes and @entity1 in offspring of @entity2 parents, and that antianxiety medication status may affect @entity1 in the offspring of @entity2 @entity0 according to genotype.

title: Association of @entity1 Symptoms in Offspring of Bipolar Parents with XXXX Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype.

answer: @entity3


abstract: We have examined the relative contribution of @entity3 , activated coagulants, procoagulants and vessel wall damage in the pathogenesis of experimental @entity0 . Using a @entity3 model in @entity1 , we found an inverse correlation between duration of @entity3 and the amount of Contact Factor and Factor Xa required to produce a @entity3 @entity2 . However, the slope of the dose-response curve for producing thrombi was different with these two coagulants. The infusion of Factor IX complex was also thrombogenic in this model despite prolonged circulation prior to @entity3 , implying that high levels of multiple procoagulants may be thrombogenic. In contrast, Factor VIII concentrates or a purified Factor IX preparation did not give thrombi under these conditions. When the vessel wall was crushed mechanically, followed by restored blood flow and subsequent @entity3 , there was essentially no formation of thrombi over the time course of the experiments. Scanning electron microscopy demonstrated that although the endothelium was swollen and damaged, there was usually no exposure of sub-endothelium and no adherence platelets. Where there was definite disruption of the endothelium, activated platelets could be seen adhering to the vessel wall. However, the blood in the segments remained fluid over a period of 30 min, despite the presence of adherent platelets. Our experiments demonstrated that the combination of vessel wall damage and @entity3 was relatively ineffective in producing @entity0 . In contrast, high levels of zymogens or small amounts of activated clotting factors, combined with local @entity3 , is a very effective thrombogenic stimulus in the venous system.

title: Experimental studies on XXXX : effect of coagulants, procoagulants and vessel contusion.

answer: @entity0


abstract: In 1985, @entity1 and @entity5 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity7 ( @entity7 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity0 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity2 mainly consisted of @entity4 and @entity6 , both of a transient nature. Seventy-three percent of @entity0 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity0 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity0 (83%) are alive at 6 years. Among the 40 @entity0 who achieved at least a PR, there were 28 with @entity3 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity7 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated @entity7 : long-term follow-up results of study by @entity1 and XXXX Group B.

answer: @entity5


abstract: In 1985, @entity1 and @entity5 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity7 ( @entity7 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity0 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity2 mainly consisted of @entity4 and @entity6 , both of a transient nature. Seventy-three percent of @entity0 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity0 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity0 (83%) are alive at 6 years. Among the 40 @entity0 who achieved at least a PR, there were 28 with @entity3 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity7 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated @entity7 : long-term follow-up results of study by XXXX and @entity5 Group B.

answer: @entity1


abstract: In 1985, @entity1 and @entity5 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity7 ( @entity7 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity0 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity2 mainly consisted of @entity4 and @entity6 , both of a transient nature. Seventy-three percent of @entity0 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity0 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity0 (83%) are alive at 6 years. Among the 40 @entity0 who achieved at least a PR, there were 28 with @entity3 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity7 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated XXXX : long-term follow-up results of study by @entity1 and @entity5 Group B.

answer: @entity7


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity1 . The purpose of this study was to examine whether @entity0 with @entity1 or @entity3 ( @entity3 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity8 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity5 . Of 16 @entity1 @entity0 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity2 positive cells. @entity0 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity3 @entity0 with @entity6 range @entity4 . Some of the @entity0 with a high percentage of @entity2 positive cells had a high percentage of @entity8 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity0 with @entity1 or @entity3 . However, @entity7 may have influenced results in the @entity3 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in @entity3 . A short review and analysis of peripheral mononuclear cell subsets in XXXX and @entity3 .

answer: @entity1


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity1 . The purpose of this study was to examine whether @entity0 with @entity1 or @entity3 ( @entity3 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity8 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity5 . Of 16 @entity1 @entity0 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity2 positive cells. @entity0 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity3 @entity0 with @entity6 range @entity4 . Some of the @entity0 with a high percentage of @entity2 positive cells had a high percentage of @entity8 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity0 with @entity1 or @entity3 . However, @entity7 may have influenced results in the @entity3 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in XXXX . A short review and analysis of peripheral mononuclear cell subsets in @entity1 and @entity3 .

answer: @entity3


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity1 . The purpose of this study was to examine whether @entity0 with @entity1 or @entity3 ( @entity3 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity8 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity5 . Of 16 @entity1 @entity0 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity2 positive cells. @entity0 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity3 @entity0 with @entity6 range @entity4 . Some of the @entity0 with a high percentage of @entity2 positive cells had a high percentage of @entity8 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity0 with @entity1 or @entity3 . However, @entity7 may have influenced results in the @entity3 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in @entity3 . A short review and analysis of peripheral mononuclear cell subsets in @entity1 and XXXX .

answer: @entity3


abstract: To develop restriction enzymes that are useful for genome analysis, we previously performed screening and isolated Sse8387I from Streptomyces sp. strain 8387. Sse8387I is a restriction enzyme that recognizes 5'-CCTGCA/GG-3' and cleaves DNA at the site shown by the diagonal (Nucleic Acid Res., 18, 5637-5640). The present study evaluated the effects of methylation that is important when Sse8387I is used for genome analysis. Sse8387I lost cleavage activity after methylation of @entity1 or methylation of @entity2 at any site in the recognition sequence. However, the recognition sequence of Sse8387I contains no CG sequence, which is the @entity0 methylation sequence. In addition, we evaluated the effects of methylation of CG at sites other than the recognition sequence. The cleavage activity of Sse8387I was maintained even when CG sequences were present immediately before or after, or near the recognition sequence, and @entity2 was methylated. These results suggest that CG methylation does not affect the cleavage activity of Sse8387I. Therefore, Sse8387I seems to be very useful for @entity0 genome analysis.

title: Sse8387I, a useful eight base cutter for XXXX genome analysis (influence of methylation on the activity of Sse8387I).

answer: @entity0


abstract: UNASSIGNED: Despite extensive research over the years, there still exists some debate as to what constitutes the optimal therapeutic strategy to promote recovery following @entity1 . Due to the complexity of injured brain pathophysiology, treatment approaches should ideally address numerous factors, ultimately aiming to promote tissue protection, axonal regrowth and functional recovery. In this study we extend our understanding of the effects of bone marrow stromal cell (BMSC) treatment following experimentally induced @entity2 in @entity0 . Focal @entity3 was experimentally induced in @entity0 by placing a preformed clot into the middle cerebral artery. Animals were injected intravenously with BMSCs at 24 hr after @entity1 and were sacrificed 7 days post injury. When administered BMSCs following @entity1 , neurological outcome was significantly improved relative to controls. There was an increase in the number of BMSCs labelled with BrdU present in the injured hemisphere of the brain compared to the non-injured side. Furthermore, administration of BMSCs also led to increases in @entity4 , vascularization and endogenous proliferation. These findings provide insight into the mechanisms of action of BMSC treatment and further argue for the therapeutic potential of BMSCs as an effective treatment following @entity1 . This article is protected by copyright. All rights reserved.

title: Multipotent Bone Marrow Stromal Cell Therapy Promotes Endogenous Cell Proliferation Following XXXX .

answer: @entity2


abstract: BACKGROUND:: There is a theoretical concern that a @entity1 may be dislodged distally when crossing the occluded segment during recanalization of a complete occlusion. OBJECTIVE:: To assess the immediate post-procedural brain diffusion weighted image (DWI) findings following endovascular recanalization using an embolic protection device for proximal internal carotid artery ( @entity3 ) occlusion. MATERIALS AND METHODS:: We retrospectively identified 12 @entity0 who underwent stent implantation for sudden symptomatic occlusion of the proximal @entity3 . In 8 @entity0 , no additional intracranial occlusions were identified. In 4 @entity0 , an additional intracerebral @entity1 was detected in the middle cerebral artery (MCA). Distal protection devices were used in all cases. We evaluated the presence and amount of retrieved @entity2 in the distal protection devices. The incidence and location of @entity4 were determined using DWI. RESULTS:: Recanalization of the proximal @entity3 was achieved in all @entity0 . After complete occlusion of the proximal @entity3 was demonstrated, primary passage of the embolic protection device through the occluded @entity3 was gently navigated in 7 @entity0 . However, this was not possible in 5 @entity0 . 3 @entity0 developed new lesions on post-procedural DWI. Of the 12 @entity0 in which distal protection devices were used, debris was detected in 7 @entity0 . CONCLUSION:: In endovascular revascularization of proximal @entity3 occlusion, @entity4 occur less frequently than reported in a systematic review of the DWI literature. The real risk of dislodging thrombi appears to be from plaque fragment mobilization by angioplasty, rather than crossing an occluded segment.

title: What is the real risk of dislodging thrombi during endovascular revascularization of a proximal XXXX occlusion?

answer: @entity3


abstract: BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some @entity1 types. OBJECTIVE: To investigate whether @entity3 positive expression is an indicator of prognosis in @entity0 with @entity2 . METHODS: Forty-seven @entity0 treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to @entity3 expression in an immunohistochemical study: the @entity3 negative group (n = 12 @entity0 ) and the @entity3 positive group (n = 35 @entity0 ). The clinicopathologic features and survival data for @entity0 in the @entity3 positive group were compared with data from the @entity0 in the @entity3 negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced @entity0 survival. RESULTS: @entity3 positive expression was observed in approximately 74.5% of @entity0 with @entity2 . @entity0 in the @entity3 positive group had lower overall survival rates and median survival time than those in the @entity3 negative group (overall 2-year actuarial survival rates, 8.6% for the @entity3 positive group vs 16.7% for the @entity3 negative group; overall 2-year median survival time, 12.9 months for the @entity3 positive group vs 17.9 months for the @entity3 negative group, P = .019). @entity3 positive expression in @entity1 cells also was correlated with a shorter interval to @entity1 recurrence (median interval to recurrence, 5.9 months in the @entity3 positive group vs 8.3 months in the @entity3 negative group, P = .002). Univariate and multivariate analyses showed that @entity3 positive expression was an independent prognostic factor. CONCLUSION: @entity3 positive expression can be used as a potential molecular risk factor in @entity0 with @entity2 .

title: 14-3-3   positive expression is associated with a poor prognosis in @entity0 with XXXX .

answer: @entity2


abstract: BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some @entity1 types. OBJECTIVE: To investigate whether @entity3 positive expression is an indicator of prognosis in @entity0 with @entity2 . METHODS: Forty-seven @entity0 treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to @entity3 expression in an immunohistochemical study: the @entity3 negative group (n = 12 @entity0 ) and the @entity3 positive group (n = 35 @entity0 ). The clinicopathologic features and survival data for @entity0 in the @entity3 positive group were compared with data from the @entity0 in the @entity3 negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced @entity0 survival. RESULTS: @entity3 positive expression was observed in approximately 74.5% of @entity0 with @entity2 . @entity0 in the @entity3 positive group had lower overall survival rates and median survival time than those in the @entity3 negative group (overall 2-year actuarial survival rates, 8.6% for the @entity3 positive group vs 16.7% for the @entity3 negative group; overall 2-year median survival time, 12.9 months for the @entity3 positive group vs 17.9 months for the @entity3 negative group, P = .019). @entity3 positive expression in @entity1 cells also was correlated with a shorter interval to @entity1 recurrence (median interval to recurrence, 5.9 months in the @entity3 positive group vs 8.3 months in the @entity3 negative group, P = .002). Univariate and multivariate analyses showed that @entity3 positive expression was an independent prognostic factor. CONCLUSION: @entity3 positive expression can be used as a potential molecular risk factor in @entity0 with @entity2 .

title: 14-3-3   positive expression is associated with a poor prognosis in XXXX with @entity2 .

answer: @entity0


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity1 (OSSN) ( @entity5 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity7 ) eye drops (1 million units/cc) 4 times daily and @entity7 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity1 control. @entity0 were 3 @entity0 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity0 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity0 had chronic discharge and @entity2 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity4 , @entity6 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity1 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity0 were treated with topical and injection @entity7 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity0 continue on chronic maintenance @entity7 topically. There were no recurrences, and @entity7 injection side effects of @entity3 and chills were minor, lasting 1 day. No @entity0 required surgical removal of @entity1 from the socket and no @entity0 required exenteration. CONCLUSIONS: @entity0 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity7 could represent a potentially effective therapy for this condition.

title: Ocular surface @entity1 ( XXXX ) of the socket: management of extensive @entity1 with interferon.

answer: @entity5


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity1 (OSSN) ( @entity5 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity7 ) eye drops (1 million units/cc) 4 times daily and @entity7 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity1 control. @entity0 were 3 @entity0 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity0 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity0 had chronic discharge and @entity2 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity4 , @entity6 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity1 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity0 were treated with topical and injection @entity7 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity0 continue on chronic maintenance @entity7 topically. There were no recurrences, and @entity7 injection side effects of @entity3 and chills were minor, lasting 1 day. No @entity0 required surgical removal of @entity1 from the socket and no @entity0 required exenteration. CONCLUSIONS: @entity0 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity7 could represent a potentially effective therapy for this condition.

title: Ocular surface XXXX ( @entity5 ) of the socket: management of extensive @entity1 with interferon.

answer: @entity1


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity1 (OSSN) ( @entity5 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity7 ) eye drops (1 million units/cc) 4 times daily and @entity7 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity1 control. @entity0 were 3 @entity0 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity0 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity0 had chronic discharge and @entity2 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity4 , @entity6 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity1 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity0 were treated with topical and injection @entity7 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity0 continue on chronic maintenance @entity7 topically. There were no recurrences, and @entity7 injection side effects of @entity3 and chills were minor, lasting 1 day. No @entity0 required surgical removal of @entity1 from the socket and no @entity0 required exenteration. CONCLUSIONS: @entity0 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity7 could represent a potentially effective therapy for this condition.

title: Ocular surface @entity1 ( @entity5 ) of the socket: management of extensive XXXX with interferon.

answer: @entity1


abstract: Stereotactic adrenal medullary transplantation into the striatum was performed in 5 @entity0 with severe @entity1 . Four @entity0 had previously been treated with thalamotomies and all were on L-dopa therapy with significant side effects. All 5 @entity0 had shown marked disability before the procedure. Autologous adrenal medullary tissue was sliced into 20-30 fragments and transplanted into two sites of the caudate nucleus, one at the ventricular surface and the other in the head of the nucleus. The cases were followed for 4-5 years (mean 4.5 years), except for 1 @entity0 who died of unrelated causes 22 months after the procedure. Initial bilateral symptom improvement was observed in all cases for 9-21 months (mean 15.2 months) after transplantation without L-dopa therapy. Later, these improvements progressively deteriorated. L-dopa therapy had to be resumed for all. MRI on the long-term follow-up showed the transplanted tissue as a low signal intensity area surrounded by high intensity spots in T1- and T2-weighted images. Compared to previous MR studies, the transplanted tissue was shrunken and presumed nonviable.

title: Long-term follow-up results of stereotactic adrenal medullary transplantation in XXXX .

answer: @entity1


abstract: PURPOSE: To identify factors influencing visual outcomes in @entity0 with @entity2 (MA). METHODS: We retrospectively reviewed the charts of 13 eyes of 13 @entity0 with @entity1 MAs. We evaluated factors. including age, blood pressure, ocular perfusion pressure, optic disc-MA distance, MA-fovea distance, the area of the @entity1 , the time between onset and treatment, initial visual acuity, and the presence of @entity1 . Additionally, we measured the retinal cross-sectional area of the fovea with optical coherence tomography (OCT). RESULTS: There were significant differences in MA-fovea distance, area of the @entity1 , and visual outcome in eyes with or without @entity1 (p < 0.05). Spearman's correlation analysis showed a significant negative correlation between visual outcome (logMAR) and disc-MA distance (rS = -0.61, p < 0.05), as well as MA-fovea distance (rS = -0.79, p < 0.01). A multivariate analysis showed an independent negative correlation between visual outcome and MA-fovea distance (Stdb = -0.66, t = 3.21, p < 0.01). In addition, there was a significant positive correlation between MA-fovea distance and the affected-/healthy-eye ratio of outer-retinal-layer cross-sectional area in the fovea (rS = 0.64, p < 0.05). The cutoff value of MA-fovea distance for @entity1 was 3000 microns, with a sensitivity of 100, specificity of 77.8, positive predictive value of 66.7 and a negative predictive value of 100. CONCLUSIONS: When @entity1 MAs are located closer to the fovea, the outer retinal layer is more severely affected and visual outcomes are poorer. @entity1 should be considered even when it is not apparent, especially when the @entity1 MA is located within 3000 microns of the fovea.

title: [Clinical Research of Factors Influencing Visual Outcomes in @entity0 with XXXX ].

answer: @entity2


abstract: PURPOSE: To identify factors influencing visual outcomes in @entity0 with @entity2 (MA). METHODS: We retrospectively reviewed the charts of 13 eyes of 13 @entity0 with @entity1 MAs. We evaluated factors. including age, blood pressure, ocular perfusion pressure, optic disc-MA distance, MA-fovea distance, the area of the @entity1 , the time between onset and treatment, initial visual acuity, and the presence of @entity1 . Additionally, we measured the retinal cross-sectional area of the fovea with optical coherence tomography (OCT). RESULTS: There were significant differences in MA-fovea distance, area of the @entity1 , and visual outcome in eyes with or without @entity1 (p < 0.05). Spearman's correlation analysis showed a significant negative correlation between visual outcome (logMAR) and disc-MA distance (rS = -0.61, p < 0.05), as well as MA-fovea distance (rS = -0.79, p < 0.01). A multivariate analysis showed an independent negative correlation between visual outcome and MA-fovea distance (Stdb = -0.66, t = 3.21, p < 0.01). In addition, there was a significant positive correlation between MA-fovea distance and the affected-/healthy-eye ratio of outer-retinal-layer cross-sectional area in the fovea (rS = 0.64, p < 0.05). The cutoff value of MA-fovea distance for @entity1 was 3000 microns, with a sensitivity of 100, specificity of 77.8, positive predictive value of 66.7 and a negative predictive value of 100. CONCLUSIONS: When @entity1 MAs are located closer to the fovea, the outer retinal layer is more severely affected and visual outcomes are poorer. @entity1 should be considered even when it is not apparent, especially when the @entity1 MA is located within 3000 microns of the fovea.

title: [Clinical Research of Factors Influencing Visual Outcomes in XXXX with @entity2 ].

answer: @entity0